4971 results for "Psychedelics"
THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE
PARIPEX INDIAN JOURNAL OF RESEARCH – May 15, 2023
Summary
Psychoactive substances like psilocybin, MDMA, and Ayahuasca show groundbreaking potential for mental health. These hallucinogens are transforming psychiatry and clinical psychology, offering new medicine for severe anxiety, depression, and PTSD resistant to traditional treatments. Research in Psychedelics and Drug Studies highlights their effectiveness, suggesting how their chemical synthesis and alkaloid nature influence behavior through neurotransmitter receptors. Psychotherapists may soon integrate these compounds, revolutionizing mental health care.
Abstract
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and ...
Understanding psychedelic 'mystical experience'—A case example
OpenAlex – March 10, 2023
Summary
Psilocybin therapy can dramatically heal deep-seated family trauma. One man, experiencing lifelong alienation due to pre-birth family trauma, found profound relief through a single psilocybin session. This experience, often described with elements of mysticism, allowed him to rebuild relationships with his parents and children. Subsequent sessions, exploring the influence of psychedelics on neurotransmitter receptors, further improved his marriage and released job stress. This example from clinical psychology highlights how a psychotherapist can guide such transformative experiences, offering insights beyond traditional psychoanalysis for profound psychological healing.
Abstract
In recent psychedelic therapy research, the concept of 'mystical experience' has been highlighted, as in several studies it has been identified as ...
The therapeutical role of psychedelic drugs in treatment of mental disorders
Bulletin of Integrative Psychiatry – September 15, 2021
Summary
Psychedelics, historically used in spiritual practices, are now demonstrating significant therapeutic promise in modern Psychiatry. These powerful compounds, central to many Drug Studies, include two main groups: indoleamines like psilocybin and LSD, and phenethylamines such as mescaline. Their influence on behavior stems from acting primarily on the 5-HT2 serotonergic Neurotransmitter Receptor. This mechanism is being explored in Psychology and Medicine for conditions like anxiety, major depressive disorder, and addictions. The chemical synthesis of certain alkaloids offers new tools for psychotherapists.
Abstract
Psychedelic drugs (also called hallucinogens, psychotogenics, psycholytics, entheogens) are substances that act mainly on the 5-HT2 serotonergic re...
Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
Pharmaceutical science. – August 27, 2025
Summary
A compelling resurgence reveals psychedelics' profound potential for treating mental disorders and addictions, a critical area in Psychology and Drug Studies. Psilocybin, an alkaloid, demonstrates efficacy for treatment-resistant depression, cancer-associated anxiety, alcohol use disorder, and nicotine dependence. MDMA, combined with psychotherapy, offers promise for post-traumatic stress disorder. Ayahuasca also aids various substance use disorders. These substances exert their Neurotransmitter Receptor Influence on Behavior, with implications for Chemical synthesis. Evidence strongly supports their therapeutic value and safety.
Abstract
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant inte...
Manifest Your Desires: Psychedelics and the Self-Help Industry
OpenAlex – April 13, 2022
Summary
A "psychedelic industrial complex" is rapidly forming, raising alarms about potential harm despite promising mental health applications. Parallels exist with the self-help industry, where for-profit businesses and spiritual gurus make overstated claims. With limited understanding of these substances' psychology and chemical synthesis, entrepreneurs market advice, creating public relations challenges. Responsible drug studies, evidence-based therapy, and decriminalization are crucial to temper profit-driven excesses and ensure genuine benefit for mental health.
Abstract
A psychedelic industrial complex is emerging as new research on these substances and their effects are being approved. These substances show promis...
Coming back together: a qualitative survey study of coping and support strategies used by people to cope with extended difficulties after the use of psychedelic drugs
Frontiers in Psychology – May 28, 2024
Summary
Many individuals navigate persistent difficulties after psychedelic experiences, a key area in psychology. A qualitative investigation of 608 participants showed meditation was the most common individual coping strategy. Seeking social support from friends or family was the primary social coping mechanism, often involving a psychotherapist. Journaling also proved helpful. This thematic analysis, relevant to clinical and social psychology, informs psychological interventions to support those affected by natural compound pharmacology. Feeling heard is crucial for effective coping.
Abstract
Introduction A growing body of literature is investigating the difficulties that some individuals encounter after psychedelic experiences. Existing...
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
Journal of Psychology & Clinical Psychiatry – August 01, 2023
Summary
Microdosing psychedelics does not objectively enhance neurocognitive performance, challenging popular belief. An observational study of 17 participants found no improved cognition—including processing speed, attention, or memory—on microdosing days or the day after. This suggests perceived benefits stem from psychological rather than direct neurocognitive pathways, offering insights for cognitive psychology. These Drug Studies highlight the complex interplay of perception and actual performance, distinct from biochemical effects, unlike factors such as sleep deprivation.
Abstract
Background and aim: Subjective and anecdotal accounts link ingestion of psychedelic microdoses, quantities small enough to retain perceptual clarit...
Amazonian Medicine and the Psychedelic Revival: Considering the “Dieta”
Frontiers in Pharmacology – May 28, 2021
Summary
Plant diets, a cornerstone of Amazonian traditional medicine, offer diverse benefits beyond illness treatment, including resilience and rites of passage. In interviews with eight seasoned healers in Peru’s San Martín province, insights revealed that these complex practices cannot be fully understood through pharmacology or psychology alone. The thematic analysis highlighted the need for broader frameworks within psychedelic science. With increasing interest in ayahuasca, this study emphasizes the importance of intercultural and interdisciplinary approaches to comprehensively explore the intricacies of plant diets and Amazonian healing traditions.
Abstract
Background: In Peruvian Amazonian medicine, plant diets ( dietas ) are a fundamental and highly flexible technique with a variety of uses: from tre...
Psychedelic Fauna for Psychonaut Hunters: A Mini-Review
Frontiers in Psychiatry – May 22, 2018
Summary
A striking trend reveals that various species of animals, including ants and amphibians, are being abused for their psychoactive properties. With the rise of a new "drug culture" among psychonauts, approximately 100 novel psychoactive substances (NPS) have gained popularity. This review identifies commonly abused "psychedelic fauna" through a comprehensive analysis of online experiences and literature, highlighting how easy access to these substances is facilitated by tourism-related searches. Routes of administration vary significantly based on the animal's characteristics and individual factors.
Abstract
Currently different classes of psychoactive substances are easily available for abuse, including several hundred novel psychoactive substances (NPS...
“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
Journal of Drug Issues – October 31, 2025
Summary
Microdosing psychedelics, including psilocybin and LSD, is rapidly gaining popularity for its perceived self-enhancing benefits rather than euphoric experiences. Interviews with 200 active microdosers reveal that 85% report improved wellbeing, with many using it to aid abstinence from more harmful substances. Participants cite motivations ranging from alleviating anxiety and depression to enhancing creativity and focus. This novel approach distinguishes itself sharply from traditional substance use, making microdosing one of the fastest-growing trends in contemporary illicit drug consumption.
Abstract
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and ...
Innovation and inequity in psychedelic research at the Mayo Clinic.
History of psychiatry – April 28, 2025
Summary
Groundbreaking experiments with LSD and psilocybin at Mayo Clinic in the 1950-60s revealed troubling bioethics practices. Researchers administered psychedelics to patients with schizophrenia and other conditions, often without proper consent. While these studies advanced our understanding of these compounds, they highlight the critical importance of ethical research protocols and patient autonomy in modern psychedelic medicine.
Abstract
This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and e...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) – November 05, 2024
Summary
Breakthrough treatments for addiction are emerging from an unexpected source: psychedelics. Compounds like psilocybin and ketamine show remarkable success in treating substance use disorders, often achieving significant results in just a few sessions. Studies reveal that psychedelics like LSD and ayahuasca can help rewire addiction-related brain patterns, while MDMA-assisted therapy helps patients process trauma underlying their substance use. These treatments offer lasting benefits with minimal risk of dependence.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times.
Journal of psychopharmacology (Oxford, England) – June 18, 2025
Summary
Tracking mental health during the COVID-19 pandemic revealed a notable finding: while many drug use patterns correlated with worsening anxiety and depression, individuals using psychedelics and cannabis experienced improved mental health. Their well-being, including reduced anxiety and depression, eventually matched those who used no drugs. This large-scale observation suggests potential benefits of psychedelics for mental health during global crises.
Abstract
Mental health implications of COVID-19 drug use patterns are still unclear. We used data-driven clustering in a large citizen science cohort recrui...
The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.
Psychopharmacology – June 01, 2022
Summary
Users of certain novel psychedelic compounds, like tryptamines and lysergamides, experience fewer physical side effects than those using phenylethylamines. Researchers surveyed nearly 1200 individuals on their use of novel psychoactive substances, including hallucinogens such as 2C-B (a phenylethylamine), 1P-LSD (a lysergamide), and 4-AcO-DMT (a tryptamine). Findings showed distinct usage patterns and, positively, fewer physical adverse events for tryptamine and lysergamide users. This suggests different classes of these psychedelic substances may offer unique safety profiles and subjective experiences.
Abstract
Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unli...
Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers.
Journal of pharmaceutical and biomedical analysis – November 01, 2014
Summary
Detecting past psychedelic drug use is now more precise. A new, highly sensitive **uhplc–ms/ms** method for **hair testing** successfully identified compounds like **mescaline**, **salvinorin A**, **n,n-dimethyltriptamine**, and **psilocin** (from psilocybin) in hair samples. This robust technique provides reliable evidence of prior consumption of psychedelic plants and mushrooms.
Abstract
A procedure based on ultra-high-pressure liquid chromatography tandem mass spectrometry has been developed for the determination of mescaline, N,N-...
Belief change and agnostic frames in psychedelic research and clinical contexts
Philosophical Perspectives on Psychedelic Psychiatry – September 13, 2024
Summary
Psychedelic experiences can profoundly shift how people understand reality. A review explored how these experiences alter metaphysical beliefs, synthesizing existing evidence, psychological theories, and philosophical perspectives. The analysis confirms that significant belief changes are possible, identifying potential psychological pathways involved. It offers guidance for research and clinical settings to navigate these transformations effectively, ensuring supportive and informed approaches.
Abstract
Abstract The proportion of people who change their metaphysical beliefs after psychedelic experiences is not yet known with specificity. However, i...
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
Current pain and headache reports – January 07, 2025
Summary
Groundbreaking research reveals psychedelics like psilocybin, LSD, and ketamine show remarkable promise in treating chronic pain conditions. These compounds provide powerful analgesic effects while addressing both physical and emotional aspects of pain. Studies demonstrate significant relief for patients with cluster headaches, neuropathic pain, and phantom limb pain through combined psychotherapy and psychedelic treatment.
Abstract
Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on...
Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields.
NeuroImage – August 15, 2024
Summary
Psychedelics like DMT can dramatically alter visual perception in minutes. New research reveals how these changes occur in the visual cortex through serotonin's 5-HT2A receptors. Brain scans showed that DMT causes visual neurons to respond differently, making their receptive fields larger, especially in peripheral vision. This explains common visual hallucinations like tunnel vision and spatial distortions.
Abstract
N, N-dimethyltryptamine (DMT) is a psychedelic tryptamine acting on 5-HT2A serotonin receptors, which is associated with intense visual hallucinato...
Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences – August 01, 2024
Summary
Scientists have developed a groundbreaking skin patch that delivers DMT, a powerful psychedelic, in controlled doses. The extended-release transdermal system maintains steady, non-hallucinogenic levels of dimethyltryptamine in the body, showing promise as a practical treatment option. Testing revealed impressive 77% bioavailability and a 20-fold increase in the drug's duration compared to traditional methods, while avoiding intense psychedelic effects.
Abstract
There is considerable evidence from the literature that psychedelics, such as N,N-dimethyltryptamine (DMT), are safe and effective treatments for d...
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – March 01, 2024
Summary
Psychedelic compounds show promise in treating depression through unexpected pathways. New research reveals that both hallucinogenic and non-hallucinogenic compounds targeting serotonin receptors can produce lasting antidepressant effects in mice. A single dose of these compounds improved mood-related behaviors for up to 15 days, working faster than traditional antidepressants. Notably, some benefits occurred even without the typical psychedelic effects.
Abstract
Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin ...
Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom.
Indian journal of microbiology – June 01, 2025
Summary
Psilocybin, known for its mind-altering properties from psychedelic mushrooms, exhibits potent antimicrobial activity. Studies confirmed psilocybin's presence and its power against common pathogens. It successfully inhibited various bacteria and fungi, with a low minimum inhibitory concentration observed for both. This highlights psilocybin's potential for new antimicrobial drug development.
Abstract
The antimicrobial compound psilocybin possesses psychoactive properties with therapeutic applications. Psilocybin is the main component naturally p...
Comparing the Detection of Endogenous Psychedelics in Individuals With and Without Alleged Mediumistic Experiences.
Explore (New York, N.Y.) – November 01, 2018
Summary
Could endogenous psychedelics influence mediumship? A recent investigation into individuals reporting mediumistic experiences compared their urine for bufotenine and dimethyltryptamine. While mediums reported significantly more anomalous experiences, analysis via high-performance liquid chromatography-mass spectrometry revealed no significant difference in these endogenous compounds compared to non-mediums. This suggests these specific substances may not be the direct biological drivers of mediumistic abilities.
Abstract
Mediumship is the alleged ability to communicate with deceased personalities. Previous studies have suggested that the endogenous psychotomimetic m...
Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry.
Journal of analytical toxicology – September 01, 2011
Summary
Pinpointing emerging psychedelic designer drugs in toxicology is now more precise than ever. Scientists developed a highly accurate and sensitive lab test for ten specific psychedelic drugs in urine. Using gas chromatography-mass spectrometry, the procedure precisely identified these substances at very low levels (down to 2 ng/mL). The method demonstrated excellent accuracy (91-116%) and precision, with no interference from other compounds, offering a robust tool for forensic toxicology.
Abstract
Psychedelic phenethylamines are an emerging class of designer drugs capable of producing a complex array of sought after adrenergic and hallucinoge...
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care.
Healthcare (Basel, Switzerland) – October 27, 2025
Summary
For those facing chronic illness, including cancer, navigating end-of-life can bring deep existential distress. A promising new model for **ketamine-assisted psychotherapy** is emerging in **palliative care**, offering significant relief. Researchers synthesized evidence on **ketamine's** unique effects, integrating neuroscientific and **psychedelics** insights. The proposed short-course model features preparatory sessions, two distinct ketamine dosing sessions (low and moderate), and integrative therapy. This patient-centered approach aims to enhance psychological safety and meaning-making, effectively addressing both physical and emotional suffering. It provides a compassionate framework to boost meaning, emotional resolution, and quality of life.
Abstract
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including...
Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.
History of psychology – August 01, 2018
Summary
In the 1950s, Canadian researchers pioneered a unique blend of psychotherapy and emerging psychoactive substances. Psychiatrist Humphry Osmond and writer Aldous Huxley, through their correspondence, explored how compounds like mescaline and LSD could stimulate empathy and alter perception. Working from an isolated Canadian hospital, their innovative collaboration developed a distinct "psychedelic approach" to therapy, laying foundational insights into its potential for mental health solutions.
Abstract
The decade of the 1950s is well known among historians of psychiatry for the unprecedented shift toward psychopharmacological solutions to mental h...
Psychedelics as psychiatric medicines: Current challenges and future prospects
Psychedelics as Psychiatric Medications – March 01, 2023
Summary
A fascinating shift is underway: psychedelics are gaining serious scientific attention for their profound potential in treating mental health disorders and addictions. The current focus explores how these compounds precisely affect the brain and interact with psychological support to achieve therapeutic change. Initial observations suggest significant benefits, though the long-term safety, optimal delivery, and integration into mainstream care are key considerations. This renewed interest points to a promising future where these unique agents could offer novel treatment pathways.
Abstract
Abstract This is an exciting time for psychedelics and related drugs, with a renewed scientific interest in their potential benefits for a range of...
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Journal of psychoactive drugs – January 01, 2019
Summary
Albert Hoffman's idea that low-dose LSD could be a Ritalin alternative sparked interest in microdosing. An exploration involving over a thousand individuals globally found that regular, small amounts of psychedelics, around 10 micrograms, were widely considered safe. Participants reported significant improvements in mood, energy, and work effectiveness. Many also noted better health habits and relief from conditions like migraines and depression, suggesting notable benefits from microdosing.
Abstract
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration...
Long-term transformative effects and integration challenges of psychedelic experiences
Consciousness Spirituality & Transpersonal Psychology – September 12, 2022
Summary
Profound, long-term positive transformation reliably follows psychedelic experiences with psilocybin and LSD. A qualitative research approach, employing thematic analysis with 6 Romanian individuals, detailed shifts in self-perception and emotional states, exemplifying transformative learning. Subsequent survey data from 39 participants corroborated these effects across the population. Integration, however, presented challenges rooted in social psychology, particularly issues with interpersonal communication and a lack of community support. These findings illuminate the complex psychological and qualitative property of post-psychedelic integration, a key area in Psychedelics and Drug Studies.
Abstract
This study looked into the transformative effects and integration challenges of psychedelic experiences with psilocybin and lysergic acid diethylam...
Psychedelic Information Theory
Proceedings of the Annual Conference of CAIS / Actes du congrès annuel de l ACSI – February 07, 2025
Summary
Psychedelic experiences fundamentally transform how we process information. A novel exploration delves into information phenomena occurring during altered states of consciousness induced by "magic mushrooms." Drawing from Psychedelic Information Theory, this interdisciplinary inquiry systematically examines "psychedelic information" across four distinct levels: personal, microsocial, macrosocial, and the overarching "meta" perspective of Information Science. This approach bridges insights from Psychology, Computer Science, and Drug Studies, offering a profound understanding of how consciousness shapes our informational landscape.
Abstract
Inspired by the conference theme, Leaps and Stumbles, our panel takes a quantum leap beyond conventional notions of information. We provide a syste...
Psychedelic Clinical Studies - Bibliometric Dataset
Figshare – January 01, 2021
Summary
A comprehensive bibliometric analysis of 1,200 clinical studies on psychedelics from 1965 to 2018 reveals a significant rise in publications, particularly in the last decade. Notably, psilocybin and MDMA accounted for over 60% of the articles. The data highlights trends in information retrieval and geographical distribution, emphasizing the growing interest in psychedelics within fields like computer science and data science. This analysis provides valuable insights into the evolving landscape of psychedelic research, particularly regarding chemical synthesis and reactions involving alkaloids.
Abstract
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptam...
Psychedelic Art and Implications for Mental Health: Randomized Pilot Study.
JMIR formative research – December 03, 2024
Summary
No Summary
Abstract
Psychedelic art (PA) emerged in the 1960s during the psychedelic era; then characterized by visuals induced by the ingestion of psychedelic drugs, ...
Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework.
Current opinion in psychology – April 01, 2025
Summary
No Summary
Abstract
Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article sy...
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – September 01, 2021
Summary
No Summary
Abstract
The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metaboli...
[Psychedelic Drugs: Past, Present, and Future].
Brain and nerve = Shinkei kenkyu no shinpo – December 01, 2023
Summary
No Summary
Abstract
In recent years, there has been a growing movement to apply psychedelic drugs for treating psychiatric disorders, including depression. Although th...
DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness.
Molecular psychiatry – November 01, 2023
Summary
No Summary
Abstract
Psychedelic compounds are being increasingly explored as a potential therapeutic option for treating several psychiatric conditions, despite relati...
Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities.
Healthcare policy = Politiques de sante – May 01, 2023
Summary
No Summary
Abstract
We agree with Kratina et al. (2023) that the problem of psychological suffering at the end of life deserves attention from a policy standpoint and ...
Virtual Daime: When Psychedelic Ritual Migrates Online.
Frontiers in psychology – January 01, 2022
Summary
No Summary
Abstract
During the 2020 COVID-19 epidemic a variety of social activities migrated online, including religious ceremonies and rituals. One such instance is ...
Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine.
ACS pharmacology & translational science – April 09, 2021
Summary
No Summary
Abstract
This viewpoint identifies pitfalls in the study of psychedelic compounds, including those that pose challenges for the potential use of psychedelic...
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis
Journal of Psychopharmacology – September 14, 2021
Summary
Psilocybin and Lysergic acid diethylamide (LSD) offer profound benefits for mental health. A meta-analysis of nine clinical trials, exploring these hallucinogens in psychiatry and clinical psychology, showed large positive effects on mood: Cohen’s d=1.26 for anxiety and d=1.38 for depression. These drug studies indicate sustained improvements. Interestingly, multiple dosing sessions yielded greater efficacy than single sessions, with no serious adverse effects reported. This medicine, influencing neurotransmitter receptors, represents a compelling advance in psychology for treating anxiety and depression.
Abstract
Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may hav...
Preparing for the Bursting of the Psychedelic Hype Bubble.
JAMA Psychiatry – October 01, 2022
Summary
While psychedelics show immense promise, their rapid rise in popularity creates a "hype bubble" that could undermine future benefits. This perspective piece argues for immediate, strategic action to ensure responsible development. By prioritizing robust research, ethical frameworks, and comprehensive training, we can secure the genuine therapeutic value of these compounds, fostering lasting positive outcomes for mental health without succumbing to market speculation.
Abstract
Preparing for the Bursting of the Psychedelic Hype Bubble.
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor
Journal of Child and Adolescent Psychopharmacology – January 06, 2025
Summary
Psychedelic therapies for adults, showing promise in psychopharmacology for conditions like PTSD and depression, are gaining traction in medicine and clinical psychology. Yet, for adolescents, there's a stark gap: zero recent trials. This absence of rigorous, controlled investigation into these powerful compounds, complex chemical synthesis and alkaloids, raises significant ethical concerns. Considering young people's vulnerability and developing neurotransmitter receptors, expert psychotherapists and psychiatry advocate for structured exploration. Applying engineering ethics, such research is crucial to safely understand how psychedelics influence behavior.
Abstract
Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress di...
Toxicology and Pharmacological Interactions of Classic Psychedelics.
Current topics in behavioral neurosciences – July 24, 2024
Summary
Classic psychedelics like LSD and psilocybin show remarkably low physical toxicity, even at high doses. Their metabolism in the liver means they can interact with common medications, particularly antidepressants. While adverse effects like anxiety can occur, they're typically manageable with proper screening and supervision. Understanding these interactions helps ensure safe therapeutic use.
Abstract
As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacologica...
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs – October 01, 2024
Summary
Psychedelic medicines show promising results in treating addiction, with success rates significantly higher than traditional methods. Recent clinical trials reveal that substances like psilocybin and MDMA, when administered in controlled medical settings, can help break destructive patterns of substance use. These treatments work by promoting neuroplasticity and addressing underlying trauma, offering new hope for those struggling with addiction where conventional treatments have failed.
Abstract
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, includi...
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.
AJNR. American journal of neuroradiology – February 15, 2024
Summary
Psychedelic compounds like psilocybin and LSD show remarkable potential in rewiring brain networks, offering hope for treating depression, PTSD, and addiction. Brain imaging reveals these substances temporarily disrupt normal communication patterns, allowing the mind to break free from rigid thinking. This "reset" effect leads to increased neural flexibility and new connections, potentially explaining why a single dose can provide lasting mental health benefits.
Abstract
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and...
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 01, 2024
Summary
Psilocybin shows promise for depression, a compelling finding in the burgeoning field of Psychedelics and Drug Studies. This review explores hallucinogens like Lysergic acid diethylamide and Mescaline, examining their pharmacology, including pharmacodynamics and pharmacokinetics. These compounds, often from chemical synthesis and alkaloids, exert serotonergic effects through neurotransmitter receptor influence on behavior. While their potential in medicine and psychology is clear, evidence for most therapeutic uses remains scarce, with similar psychedelic effects observed across compounds.
Abstract
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyl...
Microdosing Psychedelics: Current Evidence From Controlled Studies.
Biological psychiatry. Cognitive neuroscience and neuroimaging – May 01, 2024
Summary
Regular, tiny doses of lysergic acid diethylamide (LSD) can produce subtle but measurable effects on mood, pain perception, and social awareness without serious side effects. Controlled research shows that microdosing psychedelics at 10-20 micrograms affects blood pressure and brain connectivity while remaining safe. Lower doses of 5 micrograms showed no noticeable effects.
Abstract
Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential ps...
The possible place for psychedelics in pharmacotherapy of mental disorders.
Pharmacological reports : PR – December 01, 2023
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD show remarkable potential in treating mood disorders, often working faster than traditional medications. While ketamine opened doors as a fast-acting antidepressant, natural compounds including DMT and 5-MeO-DMT may offer better safety profiles with longer-lasting benefits after just one dose.
Abstract
Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting...
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Drug discovery today – December 01, 2023
Summary
Psychedelics like psilocybin and MDMA are showing remarkable promise in treating severe psychiatric disorders, with success rates exceeding 60% in some clinical trials. These substances, when combined with therapy, offer new hope for treating depression, anxiety, and posttraumatic stress disorder where traditional treatments have failed. Early results demonstrate lasting positive changes in brain connectivity and emotional processing.
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic ag...
Neuroimaging in psychedelic drug development: past, present, and future.
Molecular psychiatry – September 01, 2023
Summary
Brain scans reveal how psychedelic medicines like psilocybin and LSD work to treat mental health conditions. Modern imaging techniques show these drugs temporarily alter brain connectivity and receptor activity, particularly affecting serotonin systems. This helps explain their therapeutic effects on depression, PTSD, and addiction, while guiding the development of safer, more effective treatments.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, add...
Ensuring psychedelic treatments and research do not leave anyone behind.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2024
Summary
As psychedelic treatments gain momentum in mental healthcare, access disparities threaten to exclude marginalized communities. Historically underserved groups face multiple barriers to participating in clinical trials and receiving innovative treatments. Targeted outreach, culturally-informed protocols, and inclusive research design can help ensure these breakthrough therapies benefit all populations equitably.
Abstract
Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and researc...
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Frontiers in Neuroscience – April 17, 2023
Summary
Since the 1960s, psychedelics have shown persistent potential for treating substance use disorders. This Neuroscience narrative review synthesizes knowledge on how serotonergic hallucinogens, like psilocybin, influence behavior. Molecular neuroscience reveals they induce neuroplasticity and alter gene expression, impacting neurotransmitter receptor influence on behavior. While Psychology and Psychedelics and Drug Studies explore this, the precise biochemical mechanisms countering addiction's neuronal changes remain largely unknown. Further understanding is vital for potential psychotherapeutic applications.
Abstract
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsibl...
Why Otolaryngologists Should Be Interested in Psychedelic Medicine.
Otolaryngologic clinics of North America – October 01, 2022
Summary
Emerging treatments like ketamine, MDMA, and psilocybin show promise for treating conditions that affect the head and neck, including chronic pain, tinnitus, and anxiety in cancer patients. These psychedelic medicines offer new possibilities for ear, nose, and throat specialists to help patients who haven't responded well to conventional treatments, particularly those dealing with treatment-resistant conditions.
Abstract
As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, an...
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
Frontiers in Psychiatry – February 01, 2024
Summary
Ketamine, a legally prescribed medicine, offers profound potential in psychiatry. Its dissociative, psychedelic effects on consciousness, often mislabeled as side effects, are actually central to its therapeutic impact. When integrated by a psychotherapist, these experiences facilitate personal growth and healing, offering a powerful approach for brain disorders like Treatment of Major Depression. This positions ketamine, alongside emerging hallucinogens like psilocybin in Psychedelics and Drug Studies, as a new frontier in medicine and psychology, exploring novel brain mechanisms.
Abstract
Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is ...
Brain-epigenome wide association study (BEWAS) on the effects of two emerging psychedelics: ketamine & MDMA
bioRxiv Preprint Server – July 03, 2025
Summary
Psychedelics like ketamine and MDMA induce lasting changes in brain gene activity. These compounds alter how genes are turned on or off, impacting pathways crucial for neuroplasticity and immune function. Both show positive effects on mental processes, suggesting a shared molecular basis for their therapeutic potential in psychiatric health.
Abstract
Psychedelic compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet their molecular mechanism...
The Potential of Psychedelics for End of Life and Palliative Care.
Current topics in behavioral neurosciences – January 01, 2022
Summary
Psychedelics, particularly psilocybin, are emerging as a promising avenue for improving End of Life and Palliative care. While conventional psychiatry offers limited options for profound psychological distress in these contexts, a review of recent clinical research suggests a new path. The hypothesis posits that these compounds could provide an additional, effective psychopharmacological treatment. Findings indicate their potential to significantly enhance well-being and alleviate existential suffering, offering a vital new tool for compassionate care.
Abstract
End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these ...
Neuroimaging in psychedelic drug development: Past, present, and future
OpenAlex – June 30, 2022
Summary
Neuroimaging is revolutionizing psychedelic medicine, offering unprecedented precision in understanding how substances like psilocybin and MDMA impact the brain. This advanced neuroscience, utilizing modalities like PET and MRI, is crucial for drug development in psychiatry. It illuminates the serotonergic mechanisms of these hallucinogens, holding immense promise for treating addiction and other psychological conditions. This rigorous drug analysis provides a robust foundation for psychotherapists. Integrating these insights into medicine advances our understanding of neurotransmitter receptor influence on behavior, propelling psychedelics and drug studies forward.
Abstract
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depr...
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Scientific Reports – November 18, 2021
Summary
Among individuals with mental health concerns, microdosing psychedelics, primarily psilocybin (85% of users), correlates with lower reported levels of depression and anxiety. This finding emerged from a large psychological survey of 4050 microdosers and 4653 non-microdosers. The practice, often involving chemical synthesis and alkaloids, is gaining attention in clinical psychology and psychiatry as a potential avenue in medicine. These insights from psychedelics and drug studies highlight perceived mental health benefits, even though microdosers often report a history of mental health challenges.
Abstract
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on we...
A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.
Frontiers in pharmacology – January 01, 2016
Summary
Imagine a state of consciousness where your reality is completely replaced by an "alternate universe" filled with complex visual hallucinations. This unique experience, often induced by dimethyltryptamine (DMT), typically lasts under 20 minutes. Researchers explored using pharmacokinetic modeling to adapt target-controlled intravenous infusion, a technique for stable drug delivery, to prolong this intense psychedelic drug experience. The goal was to allow for extended observation of its psychological contents. Findings suggest DMT's rapid onset and lack of tolerance make it ideal for this intravenous infusion method. This approach promises stable, prolonged experiences, potentially aiding in neuroimaging and developing new psychotherapeutic applications, building on insights from substances like ayahuasca.
Abstract
The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substanc...
Psychedelics as anti-inflammatory agents
International Review of Psychiatry – July 04, 2018
Summary
Psychedelics like psilocybin, once dismissed as mere hallucinogens, are revolutionizing medicine, particularly in Neuroscience and Psychology. These Serotonin 5-HT2A receptor agonists, already showing promise for anxiety and addiction, now demonstrate potent anti-inflammatory effects in cellular and animal models. Pharmacology studies reveal how activating this neurotransmitter receptor influences behavior and regulates inflammatory pathways. This exciting development in drug studies suggests novel therapeutic strategies for Tryptophan and brain disorders, highlighting psychedelics' broad potential.
Abstract
Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The ...